Loading…
Reported covered position: LA/LD Rep. Tom Bliley; Counsel House Energy & Commerce Committee
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Source: Senate LDA
| ABIOMED INC |
| 37 |
| 2016–2025 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 36 | 2018–2026 |
| LOCKTON MANAGEMENT, LLC | 36 | 2017–2025 |
| WALGREEN CO | 36 | 2018–2026 |
| EDWARDS LIFESCIENCES LLC | 35 | 2018–2026 |
| PFIZER, INC. | 32 | 2016–2026 |
| BAYER CORPORATION | 31 | 2019–2026 |
| PTC THERAPEUTICS | 29 | 2019–2026 |
| RAI SERVICES COMPANY | 29 | 2019–2026 |
| Zogenix, Inc. | 29 | 2015–2022 |
| AKEBIA THERAPEUTICS, INC. | 28 | 2019–2026 |
| ALKERMES, INC. | 27 | 2015–2026 |
| ESSILORLUXOTTICA (FKA ESSILOR OF AMERICA, INC.) | 27 | 2019–2026 |
| ALLIANCE FOR REGENERATIVE MEDICINE | 21 | 2022–2026 |
| HORIZON PHARMA | 21 | 2019–2023 |
| MERCK & CO., INC. | 20 | 2015–2020 |
| STRYKER CORPORATION | 20 | 2020–2025 |
| CELGENE CORPORATION | 19 | 2015–2019 |
| BAUDAX BIO, INC. (FORMERLY KNOWN AS RECRO PHARMA, INC.) | 18 | 2019–2022 |
| ELI LILLY & CO INC | 18 | 2015–2019 |
| NATIONAL ASSOCIATION OF VISION CARE PLANS | 18 | 2022–2026 |
| NATIONAL RESILIENCE, INC. | 18 | 2020–2024 |
| THE ASSISTANCE FUND | 18 | 2021–2024 |
| AMEDISYS, INC. | 17 | 2022–2026 |
| NOVARTIS | 17 | 2023–2026 |
| BIOMARIN PHARMACEUTICAL INC. | 16 | 2023–2026 |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION | 15 | 2016–2020 |
| Alnylam Pharmaceuticals, Inc. | 15 | 2016–2019 |
| IMPOSSIBLE FOODS INC. | 15 | 2019–2022 |
| SANOFI US SERVICES INC | 15 | 2015–2018 |
| SIEMENS HEALTHINEERS | 15 | 2019–2023 |
| EPIGENOMICS INC. | 13 | 2017–2020 |
| GILEAD SCIENCES, INC. | 13 | 2015–2018 |
| AMARIN PHARM INC. | 12 | 2019–2021 |
| EISAI INC. | 12 | 2015–2017 |
| FLEXION THERAPEUTICS, INC. | 12 | 2017–2019 |
| GENENTECH INC | 12 | 2015–2018 |
| NEKTAR THERAPEUTICS | 12 | 2019–2022 |
| BREAKTHROUGH T1D (F/K/A JDRF) | 11 | 2024–2026 |
| DISPOSERX, INC. | 11 | 2019–2021 |
| NYU LANGONE HEALTH | 11 | 2024–2026 |
| ACADEMY OF NUTRITION & DIETETICS | 10 | 2025–2026 |
| CJ AMERICA, INC. | 10 | 2021–2023 |
| TARGET ALS FOUNDATION INC. | 10 | 2022–2024 |
| LYNDRA THERAPEUTICS | 9 | 2020–2022 |
| Vaxcyte, Inc. | 9 | 2024–2026 |
| CENTENE CORPORATION | 8 | 2024–2026 |
| EGALET CORPORATION | 8 | 2016–2017 |
| IOWA PRIMARY CARE ASSOCIATION (NATIONAL PRIMARY CARE ASSOCIATION HUB) | 8 | 2025–2026 |
| PERNIX THERAPEUTICS | 8 | 2015–2016 |
| BIOMERIEUX, INC. | 7 | 2024–2025 |
| REGENERON PHARMACEUTICALS, INC. | 7 | 2025–2026 |
| TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS | 7 | 2025–2026 |
| WELBEHEALTH | 7 | 2025–2026 |
| EVERYONE MEDICINES | 6 | 2024–2025 |
| JOHNSON & JOHNSON | 6 | 2016 |
| Karyopharm Therapeutics Inc. | 6 | 2018–2019 |
| RECESS | 6 | 2020–2021 |
| TRANSMEDICS | 6 | 2025–2026 |
| Altimmune, Inc. | 5 | 2020–2021 |
| BLUEBIRD BIO | 5 | 2019–2020 |
| CARDINAL HEALTH | 5 | 2017–2018 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | 5 | 2025–2026 |
| TRIO HEALTH REGULATORY ADVISORY GROUP, LLC | 5 | 2021 |
| ANCESTRY | 4 | 2019–2020 |
| EIGER BIOPHARMACEUTICALS, INC. | 4 | 2020–2021 |
| MATRIX MEDICAL NETWORK | 4 | 2020–2021 |
| NJOY, LLC | 4 | 2019 |
| OAK STREET HEALTH D/B/A CVS HEALTH | 4 | 2021–2022 |
| ORCA BIO | 3 | 2026 |
| ROIVANT SCIENCES, INC. | 3 | 2017 |
| ALG SENIOR LLC | 2 | 2025 |
| AVANIR PHARMACEUTICALS, INC. | 2 | 2018 |
| CHARLES RIVER LABORATORIES | 2 | 2022 |
| GLOBAL KRATOM COALITION | 2 | 2025 |
| MEDICOM GROUP | 2 | 2020 |
| SOBI NORTH AMERICA | 2 | 2019 |
| WAYSTAR | 2 | 2026 |
| ANHEUSER-BUSCH COMPANIES | 1 | 2018 |
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BGR GOVERNMENT AFFAIRS
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, biopharma innovation policies and Rare Pediatric Disease Priority Review Voucher program policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act S. 476/H.R.5547, and biopharma innovation policies.
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605/ H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605 / H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605 / H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605 / H.R. 8581)
Preserving Access to Home Health Act of 2022
Client: AMEDISYS, INC. · Firm: BGR GOVERNMENT AFFAIRS
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act of 2022 (S. 4605 / H.R. 8581)
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and HR 8177 - RAISE Act.
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Ariel Grace's Law
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
21st Century Cures Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Advancing Breakthrough Devices for Patients Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
FDA Device Accountability Act of 2016
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Improving Medical Device Innovation Act
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION · Firm: BGR GOVERNMENT AFFAIRS
H.R. 6 21st Century Cures Act Innovation for Healthier Americans House and Senate Agriculture Appropriations bills S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S.1622, FDA Device Accountability Act of 2015 S.2737, Improving Medical Device Innovation Act Issues related to lab developed tests H.R. 5403, To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices. proposals related to Medicare Parts A & B
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AKEBIA THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and legislation to provide greater access to kidney care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ESSILORLUXOTTICA (FKA ESSILOR OF AMERICA, INC.) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and counsel on trade related matters and enhancing vision health; DOC Access Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and counsel related to Medicare, Medicaid, and the insurance market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Providing advice, counsel, and services to support the Pharma & Biopharma Outsourcing Association's public policy priorities
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
WAYSTAR via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to prior authorization, AI, interoperability, transparency, and reimbursement matters.
Provide strategic counsel and advocate on issues related to prior authorization, AI, interoperability, transparency, and reimbursement matters.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF VISION CARE PLANS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Health reform implementation; health exchanges and essential benefits; DOC Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCA BIO via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to regulatory and reimbursement policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WELBEHEALTH via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related Medicares Program of All-Inclusive Care for the Elderly (PACE)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
IOWA PRIMARY CARE ASSOCIATION (NATIONAL PRIMARY CARE ASSOCIATION HUB) via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on federal policy issues impacting community health centers
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS)
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and policy advocacy related to to health care funding, access, and delivery, Medicaid financing and reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
FAIRMOUNT FUNDS MANAGEMENT LLC via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · Q3
Provide strategic counsel and advocate on issues related to FDA's regulatory framework for drug-drug combination products and other matters of importance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAYSTAR via BGR GOVERNMENT AFFAIRS
2026 · third_quarter · RR
Provide strategic counsel and advocate on issues related to prior authorization, AI, interoperability, transparency, and reimbursement matters.
Provide strategic counsel and advocate on issues related to prior authorization, AI, interoperability, transparency, and reimbursement matters.
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IOWA PRIMARY CARE ASSOCIATION (NATIONAL PRIMARY CARE ASSOCIATION HUB) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on federal policy issues impacting community health centers
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), White House Office
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AKEBIA THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and legislation to provide greater access to kidney care.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ESSILORLUXOTTICA (FKA ESSILOR OF AMERICA, INC.) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic guidance and counsel on trade related matters and enhancing vision health; DOC Access Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORCA BIO via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to regulatory and reimbursement policies.
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy advocacy related to to health care funding, access, and delivery, Medicaid financing and reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and counsel related to Medicare, Medicaid, and the insurance market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMEDISYS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Providing advice, counsel, and services to support the Pharma & Biopharma Outsourcing Association's public policy priorities
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FAIRMOUNT FUNDS MANAGEMENT LLC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to FDA's regulatory framework for drug-drug combination products and other matters of importance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF VISION CARE PLANS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Health reform implementation; health exchanges and essential benefits; DOC Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REGENERON PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WELBEHEALTH via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocate on issues related Medicares Program of All-Inclusive Care for the Elderly (PACE)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · Q2
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORCA BIO via BGR GOVERNMENT AFFAIRS
2026 · second_quarter · RR
Provide strategic counsel and advocate on issues related to regulatory and reimbursement policies.
PTC THERAPEUTICS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide guidance and advocacy with regard to regulations and legislation that could impact the pharmaceutical industry generally, and PTC specifically.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AKEBIA THERAPEUTICS, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic guidance and counsel on issues impacting the biopharmaceutical industry and legislation to provide greater access to kidney care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ESSILORLUXOTTICA (FKA ESSILOR OF AMERICA, INC.) via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic guidance and counsel on trade related matters and enhancing vision health
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAYER CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide lobbying support on key issues and providing intelligence and policy tracking for relevant federal policy developments that could impact the pharmaceutical and medical device industry generally, and Bayer specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN SOCIETY OF GENE AND CELL THERAPY via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Strategic advice and counsel on issues impacting gene and cell therapy development and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRANSMEDICS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy regarding utilization of donor organs for transplantation
IOWA PRIMARY CARE ASSOCIATION (NATIONAL PRIMARY CARE ASSOCIATION HUB) via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on federal policy issues impacting community health centers
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), White House Office
TEXAS ESSENTIAL HEALTHCARE PARTNERSHIPS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and policy advocacy related to to health care funding, access, and delivery, Medicaid financing and reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), White House Office
VAXCYTE, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to vaccine development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
"Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FAIRMOUNT FUNDS MANAGEMENT LLC via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to FDA's regulatory framework for drug-drug combination products and other matters of importance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WALGREEN CO. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide policy analysis, strategic advice and direct advocacy support to Walgreens related to public policy priorities for the retail pharmacy industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EDWARDS LIFESCIENCES LLC via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Advise and advocate on client's behalf regarding ongoing public policy concerns impacting the innovative biotechnology industry in Congress and throughout the Administration
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CENTENE CORPORATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Strategic guidance and counsel related to Medicare, Medicaid, and the insurance market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMEDISYS, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Strategic guidance and counsel on home health reimbursement and policy including The Preserving Access to Home Health Act (S. 4605/ H.R. 8581)
RAI SERVICES COMPANY via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide monitoring, analysis, advise and support services related to legislative and administrative policies impacting the tobacco industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Providing advice, counsel, and services to support the Pharma & Biopharma Outsourcing Association's public policy priorities
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
BREAKTHROUGH T1D (F/K/A JDRF) via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to Type 1 Diabetes policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALKERMES, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF VISION CARE PLANS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Health reform implementation; health exchanges and essential benefits; DOC Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER, INC via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Advise and advocate on clients behalf regarding ongoing public policy concerns impacting the innovative biopharmaceutical industry in Congress and throughout the Administration.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLAXOSMITHKLINE, INC via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Strategic guidance and advocacy on health care related issues to include: healthcare reform, HIV/AIDS, bio-defense, Medicare/Medicaid and FDA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
REGENERON PHARMACEUTICALS, INC. via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WELBEHEALTH via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related Medicares Program of All-Inclusive Care for the Elderly (PACE)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · 1A
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NYU LANGONE HEALTH via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
"Provide strategic counsel and policy analysis related to federal payment and policy issues and government funding impacting hospitals generally and NYU Langone Health specifically
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF NUTRITION AND DIETETICS via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic counsel and advocate on issues related to health care coverage for Medical Nutritional Therapy and Intensive behavior health and other priorities for the Academy of Nutrition and Dietetics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via BGR GOVERNMENT AFFAIRS
2026 · first_quarter · Q1
Provide strategic guidance and advocacy on issues related to regulation of, access to, and reimbursement for regenerative medicine products, and any other issues related to the Alliance for Regenerative Medicine specifically.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE